Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer’s Disease from Other Etiologies of Dementia
Table 1
Clinical characteristics of participants.
Etiologic diagnosis
value
NCI/SCI ()
AD ()
Non-AD ()
Mixed AD-VaD ()
Total ()
Age
< 0.001
Age groups
≤59 years
6 (42.9)
1 (1.4)
6 (18.8)
—
13 (8.9)
< 0.001
60-69 years
2 (14.3)
10 (14.1)
7 (21.9)
3 (10.3)
22 (15.1)
70-79 years
4 (28.6)
28 (39.4)
12 (37.5)
11 (37.9)
55 (37.7)
≥80 years
2 (14.3)
32 (45.1)
7 (21.9)
15 (51.7)
56 (38.4)
Sex
Male
7 (50.0)
24 (33.3)
13 (40.6)
11 (37.9)
55 (37.4)
0.66
Female
7 (50.0)
48 (66.7)
19 (59.4)
18 (62.1)
92 (62.6)
CDR stages
Normal
9 (64.3)
—
—
—
9 (6.1)
< 0.001
Very mild
5 (35.7)
45 (62.5)
20 (62.5)
14 (48.3)
84 (57.1)
Mild
—
17 (23.6)
7 (21.9)
12 (41.4)
36 (24.5)
Moderate
—
6 (8.3)
4 (12.5)
2 (6.9)
12 (8.2)
Severe
—
4 (5.6)
1 (3.1)
1 (3.4)
6 (4.1)
Total
14 (100.0)
72 (100.0)
32 (100.0)
29 (100.0)
147 (100.0)
PT/C ratio
< 0.001
PT/C ratio by age groups
≤59 years
—
0.07
60-69 years
70-79 years
≥80 years
Data were presented as or frequency (percentages). NCI: no cognitive impairment; SCI: subjective cognitive impairment; AD: Alzheimer’s disease; Non-AD: non-Alzheimer’s disease; Mixed AD-VaD: mixed etiology Alzheimer’s disease with either vascular cognitive impairment, subcortical ischemic vascular dementia, or cerebrovascular disease.
